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Purpose. An analysis of the clinicopathologic features and treatment of patients was performed to guide evaluation and
management of postirradiation sarcoma. Patients and Methods. Between 1994 and 2001, 25 patients with postirradiation sarcoma
were treated in one center with diﬀerent chemotherapy, mainly in neoadjuvant setting (19). Tumors for which these patients
received radiotherapy initially were mainly breast carcinoma (for 15 patients). The postirradiation sarcomas were of diﬀerent
histopathologic forms, most frequently osteosarcoma, leiomyosarcoma, and angiosarcoma. Results. Of the 25 patients, 19 were
initiallytreatedwithchemotherapy.Nineof19pretreatedpatientsachievedclinicalpartialresponse(RP=47%).Leiomyosarcomas
weregoodresponders(3/4)andundiﬀerentiatedsarcoma(3/5).RespondersweremoreoftentreatedwithMAID(6/8).Eightofthe
9 responders underwent surgery. Two patients achieved complete histological response. Seven of the 9 good responders are alive
with a median follow up of 24 months. For all treated patients, median follow up 24 months (6–84 months), overall survival and
disease free survival were, respectively, 17/25 (68%), and 14/25 (56%). Conclusion. From our data, postirradiation sarcoma should
not be managed diﬀerently from primary sarcoma. Chemotherapy has to be included in the treatment plan of postirradiation
sarcoma, in future studies.
Copyright © 2009 Gaetan des Guetz et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Among the treatment options for cancer, radiation therapy
(RT) has played an increasingly role, particularly in adjuvant
treatment.
Adverse eﬀects of radiation are sometimes observed, but
the most serious is radiation related sarcoma. Since the ﬁrst
report by Beck in 1922, many studies have documented the
associationbetweenadministrationofionizingradiationand
the subsequent development of sarcoma [1, 2].
Our population was described following the criteria ﬁrst
used by Cahan et al. of postirradiation sarcoma (PIS) [1]:
(1) histological conﬁrmation of sarcoma,
(2) prior history of RT,
(3) latency periods of several years,
(4) development of sarcoma within a previously irradi-
ated ﬁeld.
Surgery is generally considered as the main treatment of PIS.
But the poor prognostic of these types of sarcoma, because
of the late diagnosis, needs to be evaluated by the association
of chemotherapy. Although many reports in the literature
concern PIS, there are little data about chemotherapy in
the treatment of PIS. Therefore, it would be interesting to
explore the role of chemotherapy in the treatment of PIS.
In this retrospective analysis, we describe clinicopathological
elements and treatment of PIS.
2. Patients andMethods
We reviewed the medical records of the patients treated
at Institut Curie (IC) and identiﬁed in the IC sarcoma
treatment register the cases of PIS between 1994 and 2001.
Twenty ﬁve patients were registered, there were 18 women
and 7 men; see Table 12 Sarcoma
2.1. Initial Tumors Characteristics. There was a predomi-
nance of breast cancer (15). The others tumors initially
irradiated were limb sarcoma or bone metastases (4),
Hodgkin disease (2), and uterin carcinoma (1). In our
study we also had one patient with hypophysis adenoma
and two adults patients with retinoblastoma. The mean
radiation dose delivered was 53Gy (range from 30 to 72Gy)
with a mean Radiotherapy-sarcoma interval of 12 years
(4–36).
2.2. Treatments of PIS. The treatment strategy with surgery
and chemotherapy was examined.
There were two approaches to treatment, neoadjuvant or
adjuvant setting according to the stage of disease and the
possibility of surgical procedures.
In this neoadjuvant group nineteen patients with locally
advanced or metastatic disease were treated with chemother-
apy before being evaluated for surgery.
The chemotherapy consisted usually in 6 cycles of dif-
ferent regimens: cyclophosphamide 500mg/m2, vincristine
1.4mg/m2,doxorubicin 50mg/m2 onday1,anddacarbazine
(DTIC) 400mg/m2 on days 1 to 3 (CYVADIC) cycles
repeated every 28 days—the standard regimen was modiﬁed
after 1998 to MAID, combining, Doxorubicin 60mg/m2 on
day 1, ifosfamide 2.5g/m2 on days 1 to 3, and dacarbazine
800mg/m2,givenondays2,cyclesrepeatedevery28daysand
combination of Doxorubine 60mg/m2 on day 1, Cisplatine
100mg/m2 on day 1, or ifosfamide 3g/m2 on days 1 to 3
especially for osteosarcoma (Bone regimen).
The medical treatment was evaluated with clinical and
radiologicalmethods(radiography,CT-scann,orMRI)using
WHO criteria.
And it was particularly interesting, for patients who
underwent surgical resection to analyse pathologic response
(the importance of necrosis on the specimen). This is a
valuable parameter of the eﬃciency of chemotherapy.
Chemotherapy was also evaluated in terms of cardiac
toxicity.
According to the initial tumor location, thoracic surgery
(particularly chest wall surgery and breast surgery) was often
performed. Less frequently in our study, surgical resection
was also performed on the limbs and the face.
3.StatisticalAnalysis
Followup was calculated from the time of diagnosis of
postirradiationsarcomatothelastcontact.Actuarialsurvival
curves were plotted from the diagnosis of the radiation
related sarcoma using the Kaplan-Meier method. Statistical
analysis was based on Fisher’s exact test. Outcome of patients
after chemotherapy (DFS and OS) was performed.
4. Results
4.1. Characteristics of Radiation Related Sarcoma. When the
PIS was diagnosed, the median age of our patients was
5 6y e a r s( r a n g ef r o m2 8t o6 8 y e a r s ) .T h es i t e so fP I Sa r e
clearly linked to the pathology initially treated. So for the 15
women treated for breast cancer, PIS developed in breast
and chest wall. Another site of PIS was the leg for the
three patients treated initially for bone sarcoma and bone
metastasis. The pelvic PIS developed after uterin carcinoma.
The others PIS tumors were located in the neck, maxillary,
and brain for the patients, respectively, treated for Hodgkin
disease, retinoblatoma and hypophysis adenoma. PIS histo-
logic types included osteosarcoma (5), leiomyosarcoma (5),
angiosarcoma (4), Schwannosarcoma (2), Malignant Fibrous
Histiocytomas (MFH) (2), and undiﬀerentiated or clear cell
sarcoma (6). PIS tumors are high-grade sarcomas in this
study.
At diagnosis, twenty one patients had localised tumors;
median tumor size is 6cm (range from 2 to 11) in the
neoadjuvant group and 3cm (2–6) in the adjuvant group.
Four patients were metastatic (three in the lungs and one in
brain).
4.2. Results of Treatments. The 5 patients with osteosarcoma
were treated with bone regimen and Cyclophosphamide for
6 cycles and those with soft tissu sarcoma by CyVADic for 6
patients, median number cycles 3 (range 1–4) and MAID (8
patients), median cycles 6 (2–8), according to response rate.
Patients with progressive disease usually stopped treatment
after 2-3 cycles.
In the neoadjuvant group of 19 patients initially treated
withchemotherapy,beforebeingconsideredforsurgery,nine
patients achieved clinical partial response (RP = 47%). Two
diﬀerent histologic subtypes, leiomyosarcoma (4 patients)
or MFH, and undiﬀerentiated sarcomas (5 patients) were
frequently characterised. We observed higher response rate
for these tumours, respectively, 3/4 (75%) and 3/5 (60%).
This was rather diﬀerent for other subtypes as osteosarcoma
1/4 (25%), angiosarcoma 1/3 (30%), schwannosarcoma 1/2
(50%), or chondrosarcoma 0/1. Moreover with chemother-
a p ya sM A I Dw eh a v eh i g h e rr e s p o n s er a t e ,6 / 8( 7 5 % )
compared to Cyvadic, 2/6 (30%). For leiomyosarcoma, two
of the 3 responders have been treated by MAID.
For the nine clinical responders, eight patients could
be operated on. The sarcomas which were removed after
chemotherapy were examined histologically for the presence
of residual tumor. Pathological analysis found two complete
histological responses.
These characteristics of patients and results of treatments
are summarised in Table 1.
Diﬀerent types of surgery were performed for all the
patients who were operated on. According to the sites,
mainly breast and chest wall surgery for ﬁve patients,
there are two limb surgeries and one maxillary surgery
after retinoblastoma. One patient with lung metastases was
operated on, he was treated with double surgery, for sarcoma
and lung metastases. Moreover chest wall reconstruction was
often necessary in all the cases of major treatment. The
margins were not involved in these cases.
One patient had tumor located in the brain (after
hypophysis adenoma). Even with objective response, this
tumor could not be removed because of sinus cavernous
involvement.Sarcoma 3
Table 1: Characteristics of patients in neoadjuvant group.
Clinicopathologic factor Patients
Age (median, years) 56 years
Sex
Male 7
Female 18
Primary tumour
Breast cancer 15
Hodgkin disease 2
Bone metastase 1
Sarcoma
– Ewing sarcoma 2
– Osteosarcoma 1
Retinoblastomas 2
Uterus carcinoma 1
Hypophysis adenoma 1
Radiotherapy, dose delivered (mean, grays) 53
Time to development (range) 12 years (4–36)
Size, mean cm, (range) 6 (2–11)
For adjuvant group 4 (2–4)
Neoadjuvant group 6 (2–11)
Presentation for all patients:
Local disease 21
Metastatic disease: lung 2
Brain 1
Pathologic characteristics for neoadjuvant group
(response rate)
Leiomyosarcoma 4 (3/4)
Osteosarcoma 4 (1/4)
Angiosarcoma 3 (1/3)
Schwannosarcoma 2 (1/2)
Chondrosarcoma 1 (0/1)
MFH and sarcoma undiﬀerentiated 5 (3/5)
Neoadjuvant chemotherapy
(response rate)
– CYVADIC (2/6)
– MAID (6/8)
– Doxo-CDDP 5 (1/5)
Adjuvant chemotherapy
–C Y V A D I C 1
–M A I D 1
– Doxo-CDDP/ifosfamide 4
MFH: malignant ﬁbrous histiocytomas.
4.3. Followup and Outcome. For all treated patients, the
median followup reached 24 months (6–84 months).
The median overall survival (OS) was 31 months and
disease-freesurvival(DFS)was16 months forallthepatients
(Figure 1).
For the 19 patients in the neoadjuvant group, median
OS was 20 months. In the neoadjuvant group, we could dif-
ferentiate survival diﬀerences between patients treated only
with chemotherapy and those who also underwent surgery.
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Figure 1: Overall survival and disease-free survival (OS, DFS).
Even with this low number of patients, the diﬀerences are
signiﬁcant; P = .0009. Therefore survival was much better
in patients who presented clinical response and who were
operated on. It seems not possible to diﬀerentiate prognostic
according to histology, with the many diﬀerent types of
sarcomas in this small series.
On the other hand, in the adjuvant group, 1/6 (17%)
patient developed recurrent disease. For these patients, the
median OS was not reached.
One patient died, not from disease progression but from
heart failure. We also have to note that the cardiotoxicities
were observed for 2 patients showing clinical signs (grade 3-
4 of New York Heart Association (NYHA) criteria). However
the rate of LVEF could be normalized for all these patients
except one.
5. Discussion
Thesesarcomasarerare,Mark’sdataestimatedtheriskofPIS
to be from 0.03 to 0.8% with a long-term followup (ﬁfteen
years) [3]. Thus given the large number of patients who
can be cured or receiving adjuvant RT, we have to consider
that the total number of patients who develop PIS is not so
small. Ewertz and Mouridsen estimated a RR of 2.3 for bone
sarcoma and 2.1 for connective tissue sarcoma (P<. 5) [4].
Particular types of tumors are retinoblastoma. These
patients treated for retinoblatoma with deletion of the
retinoblastoma gene, an antioncogene, which also contribute
to the second primary malignancies, have increased risks of
sarcomas.Sopatientstreatedforretinoblastomaareaspeciﬁc
population but we included two patients because they were
t r e a t e da so t h e r sP I Sc a s e s[ 5].
The frequency of breast cancer and radiotherapy for
the treatment of this pathology explains the PIS female
predominance. So in our study, most of the patients were
treated for PIS after breast cancers (12 cases).
AboutpathologictypeofPIS,therewere4bonesarcomas
and 21 soft tissue sarcomas. Osteosarcoma is frequently
observed; the other subtypes are leiomyosarcoma, HFM4 Sarcoma
or ﬁbrosarcoma, and schwannoma but it is diﬃcult to
diﬀerentiate the prognosis of these subtypes [6].
As outlined in the previous studies, surgery appears
to play an important role in the improvement of survival
for PISs [6–10]. According to Pitcher, the only long-term
survivors were those who had complete surgical resection
[7]. Radical resection of the tumor is the only chance of cure
regardless of location, although centrally located PIS had a
worse prognosis than those developed in the limbs which
could be amputated or resected [8–10]. So in our study, the
majority of patients were treated with surgery, which could
explain the slightly better survival rate.
Soinourstudy,themajorityofpatientsweretreatedwith
surgery, which could explain the slightly better survival rate
compared with other published studies. Women who under-
went aggressive surgery (amputation or chest wall resection)
for PIS had a favorable outcome, therefore future patients
may beneﬁt from similar management). Because secondary
sarcomas arise in irradiated areas, surgical procedures are
often diﬃcult. Therefore, patients who develop RIS should
be evaluated at an institution which has extensive multi-
disciplinary experience with RIS (radiotherapy, surgery, and
chemotherapy) [11].
The success of surgical resection is also due to the organs
involved. For example in the brain, the surgical treatment
was not possible in our case after response to chemotherapy.
The possibility of surgical resection also depends on the
initial stage. For the four initially metastatic patients, only
one was operated on. In the Brady study only including
patients whose primary tumors were in the breast and in
whom surgery had been performed also found interesting
good results (30% survival at 5 years) [12].
The interest of this study is to consider chemotherapy
for the treatment of these types of sarcomas. Such tumors
generally are aggressive and have a high potential for local
recurrence and for metastases. Chemotherapy treatment is
logical because of the possibility of dissemination of disease
for the voluminous and particularly high histopathologic
grade of these sarcomas. So for the patients treated with
chemotherapy we obtain encouraging results. Neoadjuvant
treatment has the double beneﬁt, to evaluate chemosensi-
tivity and to begin chemotherapy without delay providing a
surgical resection sometimes not possible initially. According
to many authors, chemotherapy is rarely proposed or not
considered as the main treatment for PIS. Few reports are
interested in the role of chemotherapy in PIS [13], except
for the case of osteosarcomas which are known as being
particularly sensitive to the chemotherapy. Cefalo related a
study with ﬁve children treated for PIS osteosarcoma with
a chemotherapy protocol similar to that used in cases of
primary osteogenic sarcoma. Four patients were still living
1t o1 2y e a r sa f t e rt r e a t m e n t[ 14, 15]. We also observed
good response rate especially for leiomyosarcoma or undif-
ferentiated soft tissues sarcomas. Chemotherapy could be
proposed for PIS as neoadjuvant treatment to reduce the
surgicalintervention.Itseemsparticularlyinterestingtonote
that the response rate was higher (OR = 47%). Moreover, in
some cases the chemotherapy allows us to observe response
and so for these cases to permit later surgical resection.
Considering the better response rate for MAID regimen, it
seemsespeciallybeneﬁtforpatientswhocouldbeconsidered
for surgery to propose this type of treatment.
A few patients who were treated with neoadjuvant
or adjuvant chemotherapy are noted as long survivors.
When we examined protocols of chemotherapy based on
adriamycin, it is necessary to note the cardiac toxicity. The
heart is particularly vulnerable after breast cancer treatment.
Several reasons could explain this type of toxicity, the initial
chemotherapy for the primary tumor, often containing
anthracycline and the retreatment for secondary sarcoma
and the possible consequences of radiotherapy for breast
cancer irradiated. And so we have to mention that the
patients are generally older and have other vascular risk
factor. So it would be a necessity to prevent and follow the
development of cardiotoxicity [16].
The prognosis in patients with PIS is generally poor;
m e d i a ns u r v i v a lr a t eo fP I Si so n ey e a r[ 5]. In our study
the median OS appears to be better with a median survival
rate of 31 months. It seems necessary to compare with others
primaries sarcomas.
In the studies regarding sarcoma, prognostic factors such
as tumor size, location, surgical resection and chemosensi-
tivity are known, especially with osteosarcoma [17]. Factors
as size and site of these tumors can explain the poor
prognosis in patients with secondary sarcoma. PIS is often
diﬃcult to diagnose for patients with ﬁbrosis lesions after
radiotherapy. So the diagnosis is late and the tumor size is
larger. Therefore, for PIS and sarcoma, the prognostic factors
would be considered as the same.
To conclude, a strategy based on chemotherapy and
surgery is proposed, and the patients who beneﬁted from
complete surgical resection had the best prognosis. The
chemotherapy can be proposed as part of the strategy in
these patients. High survival rates were observed for patients
treated with surgery plus chemotherapy. PIS should be
treated in the same way as sporadic sarcomas.
Further studies should be conducted in this ﬁeld to
determine at which stage chemotherapy is most beneﬁcial,
either as neoadjuvant, adjuvant, or both, taking into account
histologic features, grade type, and location of the tumor.
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